Why HIV virions have low numbers of envelope spikes: implications for vaccine development.
作者信息
Schiller John, Chackerian Bryce
机构信息
Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, New Mexico, United States of America.
出版信息
PLoS Pathog. 2014 Aug 7;10(8):e1004254. doi: 10.1371/journal.ppat.1004254. eCollection 2014 Aug.
Abstract
摘要
相似文献
1
Why HIV virions have low numbers of envelope spikes: implications for vaccine development.
PLoS Pathog. 2014 Aug 7;10(8):e1004254. doi: 10.1371/journal.ppat.1004254. eCollection 2014 Aug.
2
Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.
Annu Rev Immunol. 2016 May 20;34:635-59. doi: 10.1146/annurev-immunol-041015-055515.
3
Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level.
Nat Med. 2010 Sep;16(9):995-7. doi: 10.1038/nm.2203. Epub 2010 Aug 29.
4
The search for effective HIV vaccines.
N Engl J Med. 2005 Aug 25;353(8):753-7. doi: 10.1056/NEJMp058146.
5
The RV144 Thai HIV vaccine trial.
Hum Vaccin. 2010 Feb;6(2):159. Epub 2010 Feb 18.
6
Role of neutralizing antibodies in HIV infection.
AIDS. 2003;17 Suppl 4:S67-71. doi: 10.1097/00002030-200317004-00008.
7
Systems biology in understanding HIV pathogenesis and guiding vaccine development.
Curr Opin HIV AIDS. 2012 Jan;7(1):1-3. doi: 10.1097/COH.0b013e32834e0667.
8
The HIV vaccine pipeline, from preclinical to phase III.
AIDS. 2001;15 Suppl 5:S147-58. doi: 10.1097/00002030-200100005-00018.
9
Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes.
Virology. 2007 Feb 20;358(2):334-46. doi: 10.1016/j.virol.2006.08.032. Epub 2006 Sep 28.
10
HIV vaccine rationale, design and testing.
Curr HIV Res. 2005 Apr;3(2):107-12. doi: 10.2174/1570162053506928.
引用本文的文献
1
Inclusion of a retroviral protease enhances the immunogenicity of VLP-forming mRNA vaccines against HIV-1 or SARS-CoV-2 in mice.
Sci Transl Med. 2025 Apr 30;17(796):eadt9576. doi: 10.1126/scitranslmed.adt9576.
2
In the activation of HPV-specific human B cells HPV-VLP vaccines mimic membrane-associated antigens.
Proc Natl Acad Sci U S A. 2025 Mar 11;122(10):e2414514122. doi: 10.1073/pnas.2414514122. Epub 2025 Mar 3.
3
Immunogenicity of HIV-1 mRNA and VLP mRNA Vaccines in Mice.
Vaccines (Basel). 2025 Jan 17;13(1):84. doi: 10.3390/vaccines13010084.
4
Mechanisms of sterilizing immunity provided by an HIV-1 neutralizing antibody against mucosal infection.
PLoS Pathog. 2024 Dec 26;20(12):e1012777. doi: 10.1371/journal.ppat.1012777. eCollection 2024 Dec.
5
Development of a Two-Component Nanoparticle Vaccine Displaying an HIV-1 Envelope Glycoprotein that Elicits Tier 2 Neutralising Antibodies.
Vaccines (Basel). 2024 Sep 18;12(9):1063. doi: 10.3390/vaccines12091063.
6
Neutralizing the threat: harnessing broadly neutralizing antibodies against HIV-1 for treatment and prevention.
Microb Cell. 2024 Jul 3;11:207-220. doi: 10.15698/mic2024.07.826. eCollection 2024.
7
Mechanical control of antigen detection and discrimination by T and B cell receptors.
Biophys J. 2024 Aug 6;123(15):2234-2255. doi: 10.1016/j.bpj.2024.05.020. Epub 2024 May 23.
8
HPV and Cervical Cancer: Molecular and Immunological Aspects, Epidemiology and Effect of Vaccination in Latin American Women.
Viruses. 2024 Feb 21;16(3):327. doi: 10.3390/v16030327.
9
Innovations in monoclonal antibody-based multipurpose prevention technology (MPT) for the prevention of sexually transmitted infections and unintended pregnancy.
Front Reprod Health. 2024 Jan 9;5:1337479. doi: 10.3389/frph.2023.1337479. eCollection 2023.
10
Antigen spacing on protein nanoparticles influences antibody responses to vaccination.
Cell Rep. 2023 Dec 26;42(12):113552. doi: 10.1016/j.celrep.2023.113552. Epub 2023 Dec 13.
本文引用的文献
1
Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination.
Curr Opin HIV AIDS. 2014 May;9(3):224-34. doi: 10.1097/COH.0000000000000049.
2
Structural insights on the role of antibodies in HIV-1 vaccine and therapy.
Cell. 2014 Feb 13;156(4):633-48. doi: 10.1016/j.cell.2014.01.052.
3
Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial.
Cancer Prev Res (Phila). 2013 Nov;6(11):1242-50. doi: 10.1158/1940-6207.CAPR-13-0203.
4
HIV-1 neutralizing antibodies: understanding nature's pathways.
Immunol Rev. 2013 Jul;254(1):225-44. doi: 10.1111/imr.12075.
5
Active immunotherapy for chronic diseases.
Vaccine. 2013 Apr 3;31(14):1777-84. doi: 10.1016/j.vaccine.2013.02.001. Epub 2013 Feb 14.
6
Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies.
J Exp Med. 2013 Feb 11;210(2):241-56. doi: 10.1084/jem.20121977. Epub 2013 Jan 28.
7
Understanding and learning from the success of prophylactic human papillomavirus vaccines.
Nat Rev Microbiol. 2012 Oct;10(10):681-92. doi: 10.1038/nrmicro2872. Epub 2012 Sep 10.
8
HPV - immune response to infection and vaccination.
Infect Agent Cancer. 2010 Oct 20;5:19. doi: 10.1186/1750-9378-5-19.
9
Molecular underpinning of B-cell anergy.
Immunol Rev. 2010 Sep;237(1):249-63. doi: 10.1111/j.1600-065X.2010.00936.x.
10
Few and far between: how HIV may be evading antibody avidity.
PLoS Pathog. 2010 May 27;6(5):e1000908. doi: 10.1371/journal.ppat.1000908.
Zotero 插件